Oct 20, 2026 05:23PM
Oct 8, 2026 06:30AM
Oct 8, 2026 06:30AM
Sep 21, 2026 04:30PM
Aug 20, 2026 06:23PM
Aug 13, 2026 04:44PM
Aug 13, 2026 08:01AM Atrium Therapeutics receives $15M milestone from Bristol Myers Squibb
Aug 13, 2026 08:00AM
Jul 14, 2026 06:30AM
Jul 14, 2026 06:30AM
May 14, 2026 04:40PM
Feb 18, 2026 05:00PM
Feb 18, 2026 05:00PM
Nov 19, 2025 09:14AM Avidity announces managed access program for DMD therapy del-zota
Nov 19, 2025 09:13AM
Nov 10, 2025 04:05PM
Oct 27, 2025 06:33AM
Oct 13, 2025 09:01AM
Oct 13, 2025 09:00AM
Oct 6, 2025 09:00AM
Sep 11, 2025 08:18AM RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
Sep 10, 2025 10:06AM
Sep 10, 2025 07:00AM
Sep 10, 2025 07:00AM
Aug 30, 2025 04:00PM
Aug 7, 2025 04:05PM
Jul 28, 2025 09:00AM
Jul 28, 2025 09:00AM Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Su
Jul 23, 2025 09:00AM
Jul 23, 2025 09:00AM
Jul 10, 2025 06:23AM
Jun 11, 2025 09:00AM
Jun 10, 2025 06:40AM
Jun 9, 2025 12:51PM
Jun 9, 2025 07:01AM Avidity Biosciences Inc. (RNA) Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD
Jun 9, 2025 07:01AM
Jun 9, 2025 07:00AM
May 13, 2025 06:59AM
May 8, 2025 04:05PM
Apr 8, 2025 09:02AM
Apr 8, 2025 09:00AM
Mar 31, 2025 09:00AM Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy
Mar 18, 2025 06:41AM
Mar 17, 2025 07:08AM
Mar 17, 2025 07:00AM
Mar 11, 2025 04:12PM
Mar 7, 2025 07:08AM
Feb 27, 2025 04:05PM
Jan 8, 2025 09:00AM Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025
Jan 6, 2025 02:00PM

335,227 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All